Table 1.
Aminoglycoside and quinolone MICs determined for the E. coli CFT073 derivative strains used in this study
| E. coli strain | MIC (μg/ml)a |
||||||
|---|---|---|---|---|---|---|---|
| AN | TM | NAL | CIP | NOR | OFX | LVX | |
| CFT073-RR | 1 | 0.25 | 2 | 0.015 | 0.06 | 0.06 | 0.03 |
| CFT073-RR/p449 | 8 | 16 | 4 | 0.06 | 0.25 | 0.06 | 0.03 |
| CFT073-RR GyrAr | 1 | 0.25 | 128 | 0.25 | 0.5 | 0.5 | 0.25 |
| CFT073-RR GyrAr/p449 | 16 | 16 | 128 | 0.5 | 2 | 0.5 | 0.125 |
a
MICs were determined for amikacin (AN), tobramycin (TM), nalidixic acid (NAL), ciprofloxacin (CIP), norfloxacin (NOR), ofloxacin (OFX), and levofloxacin (LVF) according to EUCAST guidelines.